Physician profile
Jane Kim
NPI 1891874574
$2,326.92
in general payments reported to CMS, 2019-2025
14 companies · $574 in 2025
The $574 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $31.98 · 2021: $143 · 2022: $588 · 2023: $654 · 2024: $335 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,563.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $565.86 | 2022-2025 | Infuse, Miebo, Vyzulta |
| Glaukos Corporation | $362.20 | 2023 | Kxl1b-Ce-Marked Kxlsystem, Kxl System (Not Refurbished) |
| Johnson & Johnson Vision Care, INC. | $324.03 | 2022-2025 | Acuvue |
| Dompe US, INC. | $168.21 | 2022-2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $161.83 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $149.13 | 2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $125.00 | 2021 | |
| Sun Pharmaceutical Industries INC. | $124.71 | 2022-2025 | Cequa |
| Abbvie INC. | $112.77 | 2022-2025 | |
| Alcon Vision LLC | $110.54 | 2022 | |
| Oyster Point Pharma, INC. | $52.64 | 2022-2024 | Tyrvaya |
| Harrow Eye, LLC | $31.30 | 2025 | Vevye |
| Sight Sciences, INC. | $21.46 | 2022 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.